

Rainer Tuominen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5206012/publications.pdf>

Version: 2024-02-01

13
papers

289
citations

1163117

8
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

676
citing authors

#	ARTICLE	IF	CITATIONS
1	High risk of tobacco-related cancers in <i>CDKN2A</i> mutation-positive melanoma families. <i>Journal of Medical Genetics</i> , 2014, 51, 545-552.	3.2	73
2	Targeting <i>CDK</i> 2 overcomes melanoma resistance against <i>BRAF</i> and Hsp90 inhibitors. <i>Molecular Systems Biology</i> , 2018, 14, e7858.	7.2	53
3	<i>MGMT</i> promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. <i>International Journal of Cancer</i> , 2015, 136, 2844-2853.	5.1	45
4	Silencing <i>FLI</i> or targeting <i>CD13/ANPEP</i> lead to dephosphorylation of <i>EPHA2</i> , a mediator of <i>BRAF</i> inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. <i>Cell Death and Disease</i> , 2017, 8, e3029-e3029.	6.3	35
5	<i>AXL</i> and <i>CAV-1</i> play a role for <i>MTH1</i> inhibitor <i>TH1579</i> sensitivity in cutaneous malignant melanoma. <i>Cell Death and Differentiation</i> , 2020, 27, 2081-2098.	11.2	20
6	Combining <i>ERBB</i> family and <i>MET</i> inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of <i>BRAF/NRAS</i> mutation status. <i>Cell Death and Disease</i> , 2019, 10, 663.	6.3	16
7	The role of germline alterations in the DNA damage response genes <i>BRIP1</i> and <i>BRCA2</i> in melanoma susceptibility. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 601-611.	2.8	13
8	Presence of immune cells, low tumor proliferation and wild type <i>BRAF</i> mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <i>BMC Cancer</i> , 2017, 17, 584.	2.6	11
9	Inhibiting insulin and <i>mTOR</i> signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. <i>Cell Death and Disease</i> , 2020, 11, 882.	6.3	10
10	<i>PTEN</i> 1-AS contributes to <i>BRAF</i> inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. <i>Scientific Reports</i> , 2021, 11, 11023.	3.3	6
11	Coexpression of <i>MTH1</i> and <i>PMS2</i> Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 736-740.e6.	0.7	4
12	Investigation of a putative melanoma susceptibility locus at chromosome 3q29. <i>Cancer Genetics</i> , 2014, 207, 70-74.	0.4	3
13	Novel loss-of-function variant in <i>DENND5A</i> impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma. <i>Genetics in Medicine</i> , 2022, 24, 157-169.	2.4	0